Project Grant R41EY036318
Award Date
8/1/25
Completion Date
7/31/26
Dollars Obligated
$311K
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
This $440,000 Project Grant award from the National Eye Institute (NEI), under Federal Grant Program 93.867 (Vision Research), aims to develop a novel, disease-targeted anti-angiogenic therapy for treating wet age-related macular degeneration (AMD). The key product being developed is a neutralizing monoclonal antibody that targets a new, CNV-selective angiogenic factor discovered through the awardee's comparative ligandomics technology. This approach differs from currently approved anti-VEGF...
This Project Grant award of $620,149 from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports a multi-center research program to develop advanced genome editing technologies for modifying critical genetic risk factors associated with age-related macular degeneration (AMD). The research team, led by the University of Iowa, will conduct base editing and prime editing of AMD risk loci in human cells, including induced pluripotent stem...
This federal Project Grant award, provided by the National Eye Institute (CFDA 93.867 Vision Research), supports research at the Whitehead Institute for Biomedical Research to systematically identify and characterize novel oxidative protective genes that can prevent retinal pigment epithelium (RPE) degeneration and age-related macular degeneration (AMD). The $173,016 award, effective from Aug 1, 2025 to Jul 31, 2027, will fund a project focused on three primary aims: 1) elucidating the...
This $670,496 Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports research to investigate the paradoxical role of anti-VEGF therapy in subretinal fibrosis (SRF) associated with neovascular age-related macular degeneration (NAMD). The project aims to elucidate the mechanisms by which anti-VEGF therapy at different disease stages impacts SRF, and to develop novel dual anti-angiogenesis and anti-fibrosis therapies. The...
This federal Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), is funding the development of OPGX-RHO, a single-vector gene therapy for the treatment of autosomal-dominant retinitis pigmentosa (ADRP). The $882,971 award supports two key objectives: 1) completing chemistry, manufacturing, and controls for a clinical-grade batch of OPGX-RHO, including stability studies and device compatibility testing, and 2) conducting efficacy and...
The National Eye Institute (NEI) awarded Revopsis Therapeutics, Inc. a $933,533 Project Grant under the Vision Research program (CFDA 93.867) to advance the development of their first-in-class RO-104 trispecific surrobody treatment for retinal diseases. RO-104 simultaneously targets three key angiogenic factors - VEGF-A, VEGF-C, and Ang-2 - that contribute to vision loss in conditions like age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. The award will fund...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides funding to Human Cell Co, a for-profit biotechnology research company, to develop a combination therapy for glaucoma. The award, totaling $360,897, will support research to determine if topical application of a nerve growth factor (NGF) mutein (HC201) in combination with oral nicotinamide (NAM) supplementation can more effectively improve retinal ganglion cell function compared to either treatment...
This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), will fund research to understand the genetic causes of inherited retinal degenerations (IRDs), a group of rare blinding diseases. The $1,369,782 award to the Massachusetts Eye and Ear Infirmary will support two key research aims: Developing a high-throughput splicing assay to identify rare coding and non-coding variants that lead to splicing defects and contribute to the...
This Project Grant award from the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) is funding research to develop an innovative gene therapy approach using self-amplifying and self-splicing RNA technologies. The $346,500 award, spanning September 2024 to September 2026, aims to evaluate the longevity, immunogenicity, and potential in vivo side effects of this novel mRNA-based therapy for treating inherited retinal dystrophies. The award recipient, The...
This $185,000 Project Grant award from the National Eye Institute (NEI) under CFDA 93.867 (Vision Research) supports research to discover novel disease-modifying therapies for the prevention and treatment of glaucoma. The primary awardee, the University of North Texas Health Science Center at Fort Worth, will employ computational pharmacology approaches to identify small molecule inhibitors that can interfere with the GREM1-BMP protein-protein interaction, a key pathogenic mechanism contributing...